Unity Biotechnology CFO sells shares worth $341

Published 05/02/2025, 22:40
Unity Biotechnology CFO sells shares worth $341

Lynne Marie Sullivan, the CFO and Head of Corporate Development at Unity Biotechnology, Inc. (NASDAQ:UBX), recently sold shares of the company. According to a recent filing, Sullivan sold 153 shares on February 4, 2025, at a price of $2.23 per share, totaling $341. This transaction was conducted under a Rule 10b5-1 trading plan to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this sale, Sullivan holds 55,772 shares of Unity Biotechnology, which includes Restricted Stock Units that vest over time.The company’s stock has shown strong momentum, with a remarkable 65% gain over the past six months. According to InvestingPro analysis, Unity Biotechnology currently trades near its Fair Value, maintaining a healthy liquidity position with a current ratio of 3.45. While the company operates with moderate debt levels, InvestingPro data reveals it’s quickly burning through cash - one of several key insights available to subscribers.

In other recent news, Unity Biotechnology has been making significant strides in the biotech sector. Notably, Chardan Capital Markets initiated coverage of the company’s stock with a Buy rating, highlighting the potential of Unity’s lead senolytic candidate, UBX1325, for treating diabetic macular edema (DME). UBX1325, which aims to selectively eliminate senescent cells contributing to DME, is currently undergoing a Phase 2b ASPIRE trial, with topline data expected in the first quarter of 2025.

Further, Unity Biotechnology announced the appointment of Federico Grossi, M.D., Ph.D., as its new chief medical officer. Dr. Grossi’s extensive background in clinical development and regulatory strategy, particularly in ophthalmology, is expected to advance the company’s strategic initiatives.

Meanwhile, Piper Sandler, a leading investment bank, outlined key biotech catalysts for 2025. Unity Biotechnology was among the companies with key Phase 2b readouts expected in 2025, as highlighted in the report. These developments underscore the ongoing momentum in Unity Biotechnology’s operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.